课题基金 / 基金详情

CORE--SHARED VECTOR FACILITY

CORE--SHARED VECTOR FACILITY
核心——共享矢量设施
批准号:
6356569
负责人:
RICHARD C MULLIGAN
金额:
$27.77万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-09-01 至 2001-08-31

项目摘要

项目成果

RICHARD C MULLIGAN的其他基金

相似基金

相关文献

中文摘要
翻译
Vector技术核心将为 生产和表征基因转移试剂所必需的, 哈佛基因转移项目中的每一个项目 心脏,肺和血液疾病。除了即时服务外, 与生产和传播病媒有关的职能, 研究人员在该计划中,核心的目的是高度 灵活,以便能够快速引入新的基因转移 与该计划有关的研究人员开发的技术,以及 制定必要的方法,以便迅速传播 将这些技术反馈给各个项目的研究人员。的 核心的直接能力将包括瞬态生产 常规逆转录病毒和慢病毒载体的高滴度储备液 具有多种宿主范围,产生稳定的逆转录病毒 使用多个第三和第四载体产生细胞系 代包装细胞系,生产高度浓缩 逆转录病毒/VSV G假型和标准AAV载体的产生 和第二代或第三代腺病毒载体。除了有 生产载体,核心还将提供专业知识, 设计和构建可用于获得调节的 插入基因的表达,无论是通过使用组织特异性 转录控制元件或系统,涉及调控 通过外源手段转录。 理查德·穆里根博士, 哺乳动物载体和包装细胞系的发展, 担任核心主任。
英文摘要
The Vector Technology Core will provide a centralized service for the production and characterization of gene transfer reagents necessary for each of the individual projects in the Harvard Program in Gene Transfer for Heart, Lung and Blood Disease. In addition to its immediate service functions related to the production and distribution of vectors to investigators in the Program, the Core is designed to be highly flexible, so as to be able to rapidly bring in new gene transfer technologies developed by investigators affiliated with the Program, and develop the methodology necessary to permit the rapid dissemination of those technologies back to investigators in the individual projects. The immediate capabilities of the Core will include the transient production of high titer stocks of conventional retroviral and lentivirus vectors possessing a variety of host ranges, the generation of stable retroviral vector producing cell lines using a number of third and fourth generation packaging cell lines, the production of highly concentrated retroviral/VSV G pseudotypes, and the production of standard AAV vectors and second or third generation adenoviral vectors. In addition to the production of vectors, the Core will also provide expertise in the design and construction of vectors useful for obtaining the regulated expression of inserted genes, either through the use of tissue-specific transcriptional control elements or systems involving the regulation of transcription by exogenous means. Dr. Richard Mulligan, an expert in the development of mammalian vectors and packaging cell lines, will serve as the Director of the Core.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineered in vivo nuclear fusion: application to regenerative medicine
  • 批准号:
    7833374
  • 项目类别:
  • 资助金额:
    $47.62万
  • 财政年份:
    2009
  • 负责人:
    RICHARD C MULLIGAN
  • 依托单位:
Engineered in vivo nuclear fusion: application to regenerative medicine
  • 批准号:
    7936800
  • 项目类别:
  • 资助金额:
    $48.96万
  • 财政年份:
    2009
  • 负责人:
    RICHARD C MULLIGAN
  • 依托单位:
Improving the Safety Profile of Lentiviral Vectors
  • 批准号:
    7634476
  • 项目类别:
  • 资助金额:
    $32.2万
  • 财政年份:
    2007
  • 负责人:
    RICHARD C MULLIGAN
  • 依托单位:
Improving the Safety Profile of Lentiviral Vectors
  • 批准号:
    7837755
  • 项目类别:
  • 资助金额:
    $31.88万
  • 财政年份:
    2007
  • 负责人:
    RICHARD C MULLIGAN
  • 依托单位:
海外基金